149 related articles for article (PubMed ID: 9471737)
1. [Intravesical immunotherapy with BCG vaccine in superficial carcinoma of the urinary bladder].
Pacík D; Vít V; Turjanica M
Rozhl Chir; 1997 Oct; 76(10):482-5. PubMed ID: 9471737
[TBL] [Abstract][Full Text] [Related]
2. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
Pacík D; Vít V; Turjanica M
Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
[TBL] [Abstract][Full Text] [Related]
3. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.
Tinazzi E; Ficarra V; Simeoni S; Artibani W; Lunardi C
Rheumatol Int; 2006 Apr; 26(6):481-8. PubMed ID: 16220289
[TBL] [Abstract][Full Text] [Related]
4. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
[No Abstract] [Full Text] [Related]
5. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
[TBL] [Abstract][Full Text] [Related]
6. [Granulomatous prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a case report].
Sai S; Sakakibara T; Takashi M; Sakata T; Miyake K
Hinyokika Kiyo; 1990 Aug; 36(8):953-5. PubMed ID: 2239600
[TBL] [Abstract][Full Text] [Related]
7. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
Bercovich E; Deriu M; Manferrari F; Irianni G
Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
[TBL] [Abstract][Full Text] [Related]
8. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
10. The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United Kingdom.
Robinson MR
Prog Clin Biol Res; 1989; 310():147-51. PubMed ID: 2672013
[No Abstract] [Full Text] [Related]
11. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
Patard JJ; Chopin DK
Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical BCG vaccine in bladder cancer].
Beisland HO; Sander S
Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
[TBL] [Abstract][Full Text] [Related]
13. Reactive polyarthritis induced by intravesical BCG therapy for carcinoma of the bladder.
Xerri B; Chrétien Y; Le Parc JM
Eur J Med; 1993; 2(8):503-5. PubMed ID: 8258055
[No Abstract] [Full Text] [Related]
14. Intravesical BCG therapy in patients with superficial bladder tumors.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
[No Abstract] [Full Text] [Related]
15. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
[TBL] [Abstract][Full Text] [Related]
17. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
Shiba M; Fujii T; Takatera H
Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
[TBL] [Abstract][Full Text] [Related]
18. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
Samodai L; Dankó K
Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer.
Andrade PM; Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M
Urol Oncol; 2010; 28(5):520-5. PubMed ID: 19272796
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
